Spero Therapeutics, Inc.
SPRO · NASDAQ
Earnings history and estimates
Reported and estimated revenue, EPS and post-earnings movement.
| Period | Date | Revenue actual | Revenue estimate | EPS actual | EPS estimate | 1D move |
|---|---|---|---|---|---|---|
| 2026 Q2 | August 11, 2026 | — | 281.95K | — | -0.17 | — |
| 2026 Q1 | May 13, 2026 | 258.00K | 258.00K | -0.13 | -0.18 | +13.11% |
| 2025 Q4 | March 26, 2026 | 41.30M | 26.00M | 0.53 | -0.20 | -1.69% |
| 2025 Q3 | November 13, 2025 | 3.05M | 12.00M | -0.13 | -0.25 | -1.23% |
| 2025 Q2 | August 12, 2025 | 11.80M | 11.00M | -0.03 | -0.38 | -18.01% |
| 2025 Q1 | May 13, 2025 | 5.87M | 11.00M | -0.25 | -0.55 | -5.78% |
| 2024 Q4 | March 27, 2025 | 9.36M | 6.20M | -0.38 | -0.35 | -10.88% |
| 2024 Q3 | November 14, 2024 | 13.47M | 4.13M | -0.32 | -0.27 | -5.60% |
| 2024 Q2 | August 5, 2024 | 6.02M | 4.90M | -0.33 | -0.35 | -5.22% |
| 2024 Q1 | May 15, 2024 | 4.20M | 21.53M | -0.24 | -0.07 | -3.09% |
| 2023 Q4 | March 13, 2024 | 71.83M | 18.63M | 0.96 | -0.18 | +4.82% |
| 2023 Q3 | November 13, 2023 | 25.47M | 26.63M | 0.02 | -0.15 | -1.80% |
| 2023 Q2 | August 10, 2023 | 788.00K | 11.03M | -0.23 | -0.29 | -3.45% |
| 2023 Q1 | May 11, 2023 | 740.00K | 1.00M | -0.25 | -0.35 | -3.65% |
| 2022 Q4 | March 30, 2023 | 46.30M | 22.87M | 0.55 | -0.40 | +0.69% |
| 2022 Q3 | November 14, 2022 | 1.08M | 5.42M | -0.33 | -0.34 | -7.39% |